Page 1 | Search Results | Blood | American Society of Hematology

1-7 of 7

Sort by

Sort Order Select

Journal Articles

Evolution of Blast Crisis (BC) in Chronic Myeloid Leukemia (CML) in the Imatinib-Era: A Rare Event with High Proportions of Low Risk Patients and of Early Bc; Need for Rapid Detection. Results of the German CML Study IV.

Blood (2009) 114 (22): 3287.

https://doi.org/10.1182/blood.V114.22.3287.3287

Published: 2009

Journal Articles

Prognostic Factors in Patients Receiving An Allogeneic Stem Cell Transplantation for Relapsed AML. Results of the Prospective AML 295 and 01/99 Studies

Jürgen Krauter, Gerhard Heil, Dieter Hoelzer, MD, PhD, Hans Martin, Oliver G. Ottmann, Jürgen Finke, Michael Lübbert, MD, PhD, Wolfgang Heit, Walter Fiedler, Lothar Kanz, MD, Günter Schlimok, Hartmut Kirchner, Aruna Raghavachar, Wolfram Brugger, Hartmut Döhner, Arnold Ganser, MD, PhD

Blood (2008) 112 (11): 344.

https://doi.org/10.1182/blood.V112.11.344.344

Published: 2008

Journal Articles

Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma

Bertram Glass, Marita Kloess, Martin Bentz, Günter Schlimok, Wolfgang E. Berdel, Alfred Feller, Lorenz Trümper, Markus Loeffler, Michael Pfreundschuh, Norbert Schmitz, for the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL)

Blood (2006) 107 (8): 3058–3064.

https://doi.org/10.1182/blood-2005-04-1570

Published: 2006

Journal Articles

Prospective Randomized Comparison of High Dose AraC and Autologous Peripheral Blood Stem Cell Transplantation as Late Consolidation for Patients ≤60 Years with Standard Risk AML.

Arnold Ganser, MD, Jürgen Krauter, MD, Dieter Hoelzer, MD, Oliver Ottmann, MD, Hans Martin, MD, Michael Lübbert, MD, Jürgen Finke, MD, Wolf Heit, MD, Walter Fiedler, MD, Lothar Kanz, MD, Günter Schlimok, MD, Hartmut Kirchner, MD, Aruna Raghavachar, MD, Peter Brossart, MD, Wolfram Brugger, MD, Gerhard Heil, MD

Blood (2005) 106 (11): 151.

https://doi.org/10.1182/blood.V106.11.151.151

Published: 2005

Journal Articles

Role of Consolidation Therapy in the Treatment of Patients up to 60 Years with High Risk AML.

Jürgen Krauter, MD, Gerhard Heil, MD, Dieter Hoelzer, MD, Oliver Ottmann, MD, Hans Martin, MD, Michael Lübbert, MD, Jürgen Finke, MD, Wolf Heit, MD, Walter Fiedler, MD, Lothar Kanz, MD, Peter Brossart, MD, Günter Schlimok, MD, Hartmut Kirchner, MD, Aruna Raghavachar, MD, Wolfram Brugger, MD, Arnold Ganser, MD

Blood (2005) 106 (11): 172.

https://doi.org/10.1182/blood.V106.11.172.172

Published: 2005

Journal Articles

Treatment of Adult Patients with High Risk Acute Myeloblastic Leukemia up to 60 Years: Role of Consolidation Therapy within a Prospective Multicenter Trial.

Jürgen Krauter, M.D., Gerhard Heil, M.D., Dieter Hoelzer, M.D., Oliver Ottmann, M.D., Hans Martin, M.D., Michael Lübbert, M.D., Jürgen Finke, M.D., Wolf Heit, M.D., Walter Fiedler, M.D., Dieter Hossfeld, M.D., Lothar Kanz, M.D., Günter Schlimok, M.D., Hartmut Kirchner, M.D., Aruna Raghavachar, M.D., Wolfram Brugger, M.D., Arnold Ganser, M.D.

Blood (2004) 104 (11): 618.

https://doi.org/10.1182/blood.V104.11.618.618

Published: 2004

Journal Articles

Late Consolidation for Patients with Standard Risk AML up to 60 Years: Results of a Prospective Randomized Comparison of High Dose AraC and Autologous PBSCT.

Arnold Ganser, M.D., Jürgen Krauter, M.D., Dieter Hoelzer, M.D., Oliver Ottmann, M.D., Hans Martin, M.D., Michael Lübbert, M.D., Jürgen Finke, M.D., Wolf Heit, M.D., Walter Fiedler, M.D., Dieter Hossfeld, M.D., Lothar Kanz, M.D., Günter Schlimok, M.D., Hartmut Kirchner, M.D., Aruna Raghavachar, M.D., Wolfram Brugger, M.D., Gerhard Heil, M.D.

Blood (2004) 104 (11): 145.

https://doi.org/10.1182/blood.V104.11.145.145

Published: 2004

NARROW

Evolution of Blast Crisis (BC) in Chronic Myeloid Leukemia (CML) in the Imatinib-Era: A Rare Event with High Proportions of Low Risk Patients and of Early Bc; Need for Rapid Detection. Results of the German CML Study IV.

Prognostic Factors in Patients Receiving An Allogeneic Stem Cell Transplantation for Relapsed AML. Results of the Prospective AML 295 and 01/99 Studies

Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma

Prospective Randomized Comparison of High Dose AraC and Autologous Peripheral Blood Stem Cell Transplantation as Late Consolidation for Patients ≤60 Years with Standard Risk AML.

Role of Consolidation Therapy in the Treatment of Patients up to 60 Years with High Risk AML.

Treatment of Adult Patients with High Risk Acute Myeloblastic Leukemia up to 60 Years: Role of Consolidation Therapy within a Prospective Multicenter Trial.

Late Consolidation for Patients with Standard Risk AML up to 60 Years: Results of a Prospective Randomized Comparison of High Dose AraC and Autologous PBSCT.

Email alerts

ASH Publications

American Society of Hematology

Evolution of Blast Crisis (BC) in Chronic Myeloid Leukemia (CML) in the Imatinib-Era: A Rare Event with High Proportions of Low Risk Patients and of Early Bc; Need for Rapid Detection. Results of the German CML Study IV.

Prognostic Factors in Patients Receiving An Allogeneic Stem Cell Transplantation for Relapsed AML. Results of the Prospective AML 295 and 01/99 Studies

Dose-escalated CHOP plus etoposide (MegaCHOEP) followed by repeated stem cell transplantation for primary treatment of aggressive high-risk non-Hodgkin lymphoma

Prospective Randomized Comparison of High Dose AraC and Autologous Peripheral Blood Stem Cell Transplantation as Late Consolidation for Patients ≤60 Years with Standard Risk AML.

Role of Consolidation Therapy in the Treatment of Patients up to 60 Years with High Risk AML.

Treatment of Adult Patients with High Risk Acute Myeloblastic Leukemia up to 60 Years: Role of Consolidation Therapy within a Prospective Multicenter Trial.

Late Consolidation for Patients with Standard Risk AML up to 60 Years: Results of a Prospective Randomized Comparison of High Dose AraC and Autologous PBSCT.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only